je.st
news
Gilead: Another Competitor Bites The Dust
2014-11-12 04:58:35| Biotech - Topix.net
Despite a very successful 2014 that included an almost quadrupling of earnings, investors remain overly pessimistic on the prospects of Gilead Sciences. The stock is cheap, competitors continue to fail to make inroads into its core hepatitis C franchise and sales there are just getting started and should continue to beat expectations.
Tags: dust
bites
competitor
gilead
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||